Type of Spiritual Experience
A description of the experience
Vemurafenib (INN, marketed as Zelboraf) is a B-Raf enzyme inhibitor developed for the treatment of late-stage melanoma. The name "vemurafenib" comes from V600E mutated BRAF inhibition.
At the maximum tolerated dose (MTD) of 960 mg twice a day 31% of patients get skin lesions that may need surgical removal. The BRIM-2 trial investigated 132 patients; the most common adverse events were arthralgia in 58% of patients, skin rash in 52%, and photosensitivity in 52%. In order to better manage side effects some form of dose modification was necessary in 45% of patients. The median daily dose was 1750 mg, which is 91% of the MTD.
On Feb, 9, 2016: 1,271 people reported to have side effects when taking Zelboraf. Among them, 4 people (0.16%) have Hallucination.
On Jan, 28, 2016: 1,271 people reported to have side effects when taking Zelboraf. Among them, 310 people (24.39%) have Death.
Time on Zelboraf when people have Death :
|< 1 month||1 - 6 months||6 - 12 months||1 - 2 years||2 - 5 years||5 - 10 years||10+ years|
Gender of people who have Death when taking Zelboraf :
Age of people who have Death when taking Zelboraf :
Top conditions involved for these people :
- Malignant melanoma (70 people, 22.58%)
- Bone neoplasm malignant (11 people, 3.55%)
- Metastases to lung (10 people, 3.23%)